Positive Response from US FDA to Amplia's Type D Meeting
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Amplia Receives R&D Tax Rebate Totalling $3.77 Million
- First patient dosed in new pancreatic cancer trial
- Amplia Share Purchase Plan Raises $2.65 Million
- Positive ACCENT Trial Topline Data Released
- Capital Raising Presentation
Later from Amplia Therapeutics
- Half Yearly Report and Accounts
- Key Narmafotinib Patent Granted in the U.S.
- Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th
- Additional Confirmed Response Reported as Part of Amplia Investor Presentation
- Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics